OncLive SOSS

Exploring the Role of a Novel HPV16-Targeted Cancer T-cell Stimulating Immunotherapy (TSI) (Versamune HPV) for Human Papilloma Virus (HPV) Positive Head and Neck Cancer (HNSCC) - Episode 7

Treatment Insights for R/M HPV-Positive HNSCC

February 3, 2025

Francis Paul Worden, MD, University of Michigan Comprehensive Cancer Center, Kevin Harrington, MBBS, MRCP, FRCR, FRCP, PhD, DIC

Panelists discuss key research priorities for recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC), which include expanding PDS0101/pembrolizumab trials to identify optimal patient subgroups, addressing resistance mechanisms, and exploring novel biomarkers. Emerging immunotherapy combinations and targeted therapies show promise.

Video Player is loading.

Current Time 0:00

Duration 0:00

Loaded: 0%

Stream Type LIVE

Remaining Time 0:00

EP. 1: Introduction and Incidence of HPV-Positive Head and Neck Cancer

EP. 2: Understanding HPV-Positive HNSCC: Disease Presentation and Risk Factors

EP. 3: Navigating Treatment for HPV-Positive HNSCC Patients

EP. 4: Academic Perspectives for the Management of HPV-Positive HNSCC

EP. 5: Updates From VERSATILE-002: Pembrolizumab Plus PDS0101 (HPV-16–Targeted Cancer Vaccine) in HPV-Positive HNSCC

EP. 6: Emerging Phase 3 Trial: Pembrolizumab Plus PDS0101 (HPV-16 Targeted Cancer Vaccine) in HPV-Positive HNSCC (VERSATILE-003)

EP. 7: Treatment Insights for R/M HPV-Positive HNSCC

EP. 8: Future Considerations for the Treatment of R/M HPV-Positive HNSCC

Video content above is prompted by the following:

What are the most pressing unmet needs related to the treatment of R/M HNSCC?

x